鎌状赤血球症患者のための遺伝子導入
ガンマ グロビン レンチウイルス ベクターを使用した鎌状赤血球症患者の遺伝子導入: 非盲検フェーズ 1/2 パイロット研究
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
調査の概要
詳細な説明
This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
-
Signed informed consent form.
-
Has confirmed diagnosis of sickle cell disease (SCD)
-
Has severe sickle cell disease, defined as one or more of the following:
- Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
- Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
- Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
-
Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.
-
Has adequate functional status and organ function as determined at Screening.
Exclusion Criteria
- Female subjects who are pregnant or lactating/breastfeeding.
- Female subjects who are not surgically sterile, postmenopausal or who refuse to practice effective method of birth control as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
- Any participant of reproductive potential who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
- Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
- Current diagnosis or history of hepatitis B, hepatitis C, or HIV.
- Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
- Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
- Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
- Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
- Patients with alpha thalassemia sickle cell disease.
- Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
- Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the informed consent process for subjects who decline this option.
- Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).
Other protocol-defined inclusion-exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ARU-1801
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion. |
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Grade 3 Allergic Reaction
時間枠:From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product |
From infusion (Day 0) to 30 days post-infusion
|
|
Number of Participants Grade 4 Infection
時間枠:From infusion (Day 0) to 30 days post-infusion
|
Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Grade 4 Neutropenia
時間枠:From date of chemotherapy clearance visit to to 30 days post-infusion
|
Number of participants with Grade 4 neutropenia lasting >1 month following melphalan |
From date of chemotherapy clearance visit to to 30 days post-infusion
|
|
Number of Participants With Grade 3 or 4 Toxicity Events
時間枠:From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
時間枠:From infusion (Day 0) to 30 days post-infusion
|
From infusion (Day 0) to 30 days post-infusion
|
|
|
Number of Death Due to Study Procedures
時間枠:From screening to the end of study, and up to 12 months.
|
From screening to the end of study, and up to 12 months.
|
|
|
Number of Hematological Malignancy
時間枠:From infusion (Day 0) to end of study, up to 12 months
|
Number of hematological malignancy due to vector insertion |
From infusion (Day 0) to end of study, up to 12 months
|
|
Number of Hematological Cancer
時間枠:From infusion (Day 0) to end of study, up to 12 months.
|
Number of hematological cancer related to investigational product or study medications/procedures |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Neutrophil Recovery
時間枠:From infusion (Day 0) to end of study, up to 12 months.
|
Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) < 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Platelet Recovery
時間枠:From infusion (Day 0) to end of study, up to 12 months.
|
Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count < 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days > 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
≥8x10⁶kg Viable CD34+ Cells
時間枠:Date of Enrollment to Infusion (day 0).
|
Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells |
Date of Enrollment to Infusion (day 0).
|
|
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
時間枠:Date of Enrollment to Infusion (day 0).
|
Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced |
Date of Enrollment to Infusion (day 0).
|
|
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
時間枠:Infusion (Day 0) to 1 year post infusion.
|
Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells |
Infusion (Day 0) to 1 year post infusion.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of HBF^G16D
時間枠:Infusion to 12 months post-infusion
|
Percentage of HBF^G16D relative to total Hemoglobin |
Infusion to 12 months post-infusion
|
|
Change in Proportion of Antisickling/Sickling Hemoglobin
時間枠:Enrollment to Month 24
|
Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome. |
Enrollment to Month 24
|
|
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
時間枠:Infusion to 12 months post-infusion
|
This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry. |
Infusion to 12 months post-infusion
|
|
Percent VCN at 6 Months
時間枠:Infusion to 6 months post-infusion
|
This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR). |
Infusion to 6 months post-infusion
|
協力者と研究者
捜査官
- スタディチェア:Stella M. Davies, MB BS, PhD, MRCP、Children's Hospital Medical Center, Cincinnati
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ARU-1801_Ph1_01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。